• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>CNS neuroscience & therapeutics. >Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease‐modifying therapies
【24h】

Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease‐modifying therapies

机译：接受疾病改良疗法的多发性硬化症患者中单剂量三价季节性流感疫苗的免疫原性和反应预测因子

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims To evaluate the immunogenicity and safety of a seasonal influenza vaccine in a cohort of multiple sclerosis (MS) patients receiving different immunomodulating/immunosuppressive therapies and assess predictors of immune response. Methods A prospective, multicenter, non‐randomized observational study including 108 patients receiving a trivalent seasonal influenza vaccination was conducted. Influenza‐specific antibody titers (H1N1, H3N2, and influenza B) were measured to evaluate rates of seroprotection and seroconversion/significant titer increase. Univariable and multivariable analyses were performed to identify prognostic factors of vaccination outcomes. Results Regarding the whole cohort, seroprotection rates 70% were achieved for each influenza strain. Interferon‐treated patients reached high seroprotection rates (84%). Good seroprotection rates were seen in patients treated with glatiramer acetate. In particular for H3N2, response rates were low in natalizumab‐treated patients and in the small subgroup of fingolimod‐treated patients. Patients with a previous disease‐modifying therapy and a longer disease duration were less likely to respond sufficiently. No severe adverse events were reported. MS disease activity was not increased after a one‐year follow‐up period. Conclusion Vaccination led to good immunogenicity, especially in MS patients treated with interferons and glatiramer acetate. At least for the H1N1 strain, rates of seroprotection and seroconversion/significant titer increase were high (70% and 60%, respectively) for all therapeutic subgroups. Patients with a longer duration of the disease are exposed to an increased risk of insufficient immune response to vaccination.
机译：目的在一组接受不同免疫调节/免疫抑制疗法的多发性硬化症（MS）患者中评估季节性流感疫苗的免疫原性和安全性，并评估免疫应答的预测因子。方法进行了一项前瞻性，多中心，非随机的观察性研究，包括108例接受三价季节性流感疫苗接种的患者。测量了流感特异性抗体滴度（H1N1，H3N2和乙型流感）以评估血清保护和血清转化/显着滴度增加的速率。进行单变量和多变量分析以鉴定疫苗接种结果的预后因素。结果在整个队列中，每种流感病毒株的血清保护率均> 70％。干扰素治疗的患者达到很高的血清保护率（> 84％）。醋酸格拉替雷治疗的患者具有良好的血清保护率。特别是对于H3N2，那他珠单抗治疗的患者和芬戈莫德治疗的亚组患者的反应率很低。以前曾进行过疾病缓解疗法且病程较长的患者不太可能充分做出反应。没有严重不良事件的报道。一年的随访期后，MS疾病活动没有增加。结论接种疫苗可产生良好的免疫原性，特别是在接受干扰素和醋酸格拉替雷治疗的MS患者中。至少对于H1N1菌株，所有治疗亚组的血清保护和血清转化/显着滴度增加率均很高（分别为> 70％和> 60％）。疾病持续时间较长的患者暴露于对疫苗免疫反应不足的风险增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号